S
tructural valve deterioration (SVD) because of leaflet calcification or collagen fiber disruption are the main factors limiting the durability of bioprosthetic valves (BPs) after aortic valve replacement (AVR). 1 Although SVD of BPs has long been considered a purely passive degenerative process caused by wear and tear of the valve leaflets, recent studies suggest that active and potentially modifiable mechanisms may also be involved in BP SVD. These patient-related mechanisms include lipid infiltration, inflammation, immune rejection, and active mineralization. 2 SVD may lead to hemodynamic valve deterioration (HVD), which is characterized by leaflet stiffening and progressive valve stenosis or leaflet tear with ensuing transvalvular regurgitation. 3 Although guidelines [3] [4] [5] [6] have recommended defining SVD on the basis of valve reintervention and evidence of HVD during echocardiographic follow-up, the vast majority of previous studies [7] [8] [9] [10] have used reoperation for valve hemodynamic failure as the primary end point for SVD. However, this approach may substantially underestimate the true incidence of SVD and HVD. Indeed, an important proportion of patients with significant SVD or HVD may not be reoperated because they are (1) underdiagnosed, (2) not currently at the stage of HVD severity requiring reintervention, or (3) considered too high risk for reoperation. Furthermore, there is a paucity of data on the timing of onset of SVD and associated HVD after AVR.
The objectives of this study were to determine the rate, timing, correlates, and association with clinical outcomes of HVD assessed by echocardiography after BP AVR.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Patient Population
Between January 1995 and January 2010, a total of 3132 patients underwent a surgical AVR with a BP at the Quebec Heart and Lung Institute. Of this group, 282 patients were excluded from the study because of (1) previous mitral valve repair or replacement, (2) previous aortic valve repair or replacement, (3) concomitant mitral valve surgery, (4) concomitant ascending aorta surgery, and (5) greater than or equal to moderate concomitant mitral regurgitation at the time of AVR ( Figure I in the online-only Data Supplement). Among the remaining 2850 patients, 133 died during the early postsurgical period (in-hospital mortality), and 1330 had incomplete echocardiographic follow-up data ( Figure I in the online-only Data Supplement). Thus, 1387 patients who had a complete Doppler echocardiographic follow-up for ≥2 years after AVR at our institution were included in this study. To ensure standardization of echocardiographic image acquisition and analysis, patients who underwent echocardiographic follow-up at another institution were excluded. Preoperative, operative, and postoperative clinical and echocardiographic data were prospectively gathered in an electronic database. However, the present study was not a prespecified analysis at the time of the setup of the database, and this study should thus be considered retrospective in nature. The study was approved by the institutional review board of the Institut de Cardiologie et de Pneumologie de Québec, and because this is a retrospective study, informed consent was not required.
Clinical Variables
Coronary artery disease was defined as the occurrence of previous coronary artery bypass grafting, myocardial infarction, or ≥1 stenosis ≥50% within the major epicardial coronary arteries, including the left main stem. Involvement of the left main stem was considered 2-vessel disease. Previous aorta or vascular surgery was defined by prior aortic thoraco-abdominal surgery, aortic abdominal surgery, carotid endarterectomy, or surgery involving the peripheral arterial vasculature. Lowdensity lipoprotein, high-density lipoprotein, triglycerides, and serum creatinine levels were reported at the time of surgery.
In patients with anticoagulation therapy (warfarin) before AVR, the therapy was continued without change in the postoperative period and thereafter during the rest of the followup. In patients without prior anticoagulation therapy, the protocol was use of aspirin for ≥3 months after surgery.
Transthoracic Echocardiography
Transthoracic echocardiography (TTE) examinations was performed preoperatively (baseline preoperative TTE), in the first year (baseline post-AVR TTE) postoperatively, and repeated during follow-up. All TTE examinations were conducted according to the American Society of Echocardiography guidelines. 11 Left ventricular ejection fraction was measured using the biplane Simpson method. Transprosthetic flow
Clinical Perspective
What Is New?
• Hemodynamic valve deterioration (increase in transprosthetic gradient or regurgitation) related to structural valve degeneration was documented by Doppler echocardiography in ≈30% of patients after surgical aortic valve replacement with a bioprosthetic valve.
• Hemodynamic valve deterioration was associated with a 2.2-fold higher adjusted mortality.
• Diabetes mellitus, active smoking, and renal insufficiency were associated with early (<5 years) hemodynamic valve deterioration, whereas female sex, warfarin use, and type of bioprosthesis (stented versus stentless and pericardial versus porcine) were associated with late (>5 years) deterioration.
What Are the Clinical Implications?
• After bioprosthetic valve replacement, a systematic echocardiographic follow-up should be performed to ensure adequate detection and quantitation of hemodynamic valve deterioration related to structural or nonstructural etiologies. 11 HVD was defined as proposed in recent recommendations of medical societies and groups of experts [4] [5] [6] : (1) an increase in MG ≥10 mm Hg associated with a decrease in effective orifice area or worsening of transprosthetic regurgitation ≥1/3 grade between baseline after AVR and follow-up TTEs, with last follow-up grade being at least moderate; and (2) abnormalities of valve leaflets morphology (thickening and calcification) and motion (restricted motion or flail leaflet). In this study, we primarily focused on HVD related to SVD. Thus, worsening of prosthetic regurgitation or an increase in MG related to non-SVD such as valve thrombosis, pannus, or prosthetic infective endocarditis or paraprosthetic regurgitation was not classified as HVD in this study.
Timing of HVD was defined as follows: "very early" was HVD occurring during the first 2 years after AVR; "early," HVD occurring between 2 and 5 years; "midterm," HVD occurring between 5 and 10 years; and "long-term," HVD occurring after 10 years ( Figure 1 ).
Patient-prosthesis mismatch (PPM) was calculated using the predicted indexed effective orifice area (ie, the normal reference value of effective orifice area for the model and size of BP implanted in the patient divided by the patient's body surface area). 4 
Outcome Data
Mortality data were retrospectively obtained from the Québec Institute of Statistics. To maximize the interrogation of the central Québec Institute of Statistics database, a list with multiple demographics (including first and last names, date of birth, and social security number) and a delay of 1 year between interrogation and closing follow-up dates were used.
Statistical Analysis
Categorical variables were reported as number (percentage) and continuous as mean±SD or median (25th to 75th interquartile range) depending on variable distribution. Distribution normality and homogeneity of variances of continuous variables were assessed using the Shapiro-Wilk and Levene tests, respectively. Continuous variables were then compared with ANOVA and the Tukey's range test. Categorical variables were compared by using the χ2 or Fisher exact test when appropriate. Uni-and multivariable Cox proportional hazards models were used to identify factors associated with HVD. These analyses were performed in the early phase, including the first 5 years after AVR and then in the late phase beyond 5 years. Cox models were also used to identify the factors associated with death from any 
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cause. All variables presented were tested in univariable analyses, and clinically relevant variables or variables with P value <0.10 were entered into the multivariable regression models. Cox proportional hazards regression curves were used to display adjusted cumulative hazard of death from any cause according to the presence or absence of HVD and the timing of HVD. Kaplan-Meier curves and log-rank test of the time-to-event data were used to compare the association between very early, early, midterm, and long-term HVD and death from any cause. For very early, early, and midterm HVD, the baseline (time zero) of the follow-up period was set at the date of the first echocardiographic diagnosis of HVD for patients with HVD and the end of the studied time subperiods for patients without HVD (ie, 2, 5, and 10 years, respectively). For long-term HVD, the baseline time was set at the 10 years after AVR for all patients.
A P value <0.05 was considered statistically significant. All P values were from 2-sided tests. Statistical analyses were performed with JMP V.13 (SAS) and SPSS version 20.0 software (IBM).
RESULTS

Baseline Preoperative and Postoperative Data
The mean age of the study population was 70.5±7.8 years, and 62.2% were men. Diabetes mellitus was present in 22.6%, hypertension in 61.9%, and coronary artery disease in 60.6%. The baseline preoperative characteristics of the population are presented in Table I in the online-only Data Supplement. Operative and baseline postoperative echocardiographic data are shown in Tables II and III in the online-only Data Supplement. BP implanted were stented pericardial BP in 565 (40.7%) patients, stented porcine BP in 526 (37.9%) patients, and stentless BP in 296 (21.3%) patients. Models and label sizes of the BPs are shown in Table IV in the online-only Data Supplement. One third of patients had moderate PPM (n=449, 32.4%), and 2.7% had severe PPM. The median time between AVR and the baseline postoperative TTE was 4.1 (1.3-6.5) months, and at this baseline TTE after AVR, 25.9% of the patients had a MG ≥15 mm Hg. The proportion of patients with postoperative MG ≥15 mm Hg was higher in patients with a small valve size ≤21 mm (39.1% versus 21.7%, P<0.001). Patients who were excluded from this study (ie, patients with perioperative or early postoperative death or patients who had incomplete echocardiographic follow-up) had an overall worse baseline risk profile and higher mortality rates during follow-up compared with patients included in the study (Table I and 
Incidence and Timing of HVD
The median echocardiographic follow-up was 6.2 (4.0-9.1) years after the AVR, and 428 (30.9%) patients showed signs of HVD. Among these patients, 231 (54%) with HVD only had an increase in MG (ie, prosthetic valve stenosis); 135 (31.5%) only presented a worsening in transprosthetic regurgitation; and 62 (14.5%) met both criteria. HVD was first detected at a median time of 5.8 (3.1-8.9) years after surgery. The timing of the HVD was very early in 52 patients (3.7% of the total population, 12.1% of the total subset with HVD), early in 129 patients (13.9% of the total population remaining at risk in the early phase, 30.1% of total HVD), midterm in 158 patients (41.0% of total population remaining at risk in the midterm phase, 36.9% of total HVD), and long-term in 89 patients (39.2% of total population remaining at risk at 10 years, 20.8% of total HVD) ( Figure 1 ).
The median times between surgery and HVD were 1.2 (0.9-1.6), 3.4 (2.6-4.1), 7.2 (6.1-8.4), and 12.2 (11-13.5) years for very early, early, midterm, and longterm HVD, respectively. The mean age of the patients at the time of HVD was not significantly different in very early (74.3±8.3 years), early (74.2±7.8 years), midterm (76.4±7.6 years), and long-term (75.5±7.8 years), respectively (P=0.08). The comparisons of the patients' characteristics according to the timing of HVD are available in Table V in the online-only Data Supplement). The type of HVD at the various time points is shown in Table VI in the online-only Data Supplement. For HVD occurring within the first 5 years after AVR, the predominant type of valve dysfunction was stenosis (69%) versus regurgitation or mixed (31%). In the subset of patients with HVD occurring within the first 5 years after AVR, there was no significant change in left ventricular ejection fraction from baseline after AVR to follow-up (Results in the online-only Data Supplement). For HVD occurring beyond 5 years, the predominant dysfunction was regurgitation or mixed (57%) versus stenosis (43%).
Factors Associated With HVD
The variables associated with HVD on univariable analysis were diabetes mellitus, hypertension, creatinine clearance, statin use, baseline postoperative MG ≥15 mm Hg, severe PPM, and type of BP (Table 1 ). Age at implantation was not significantly associated with HVD. Stentless BPs were associated with less HVD compared with stented BPs. Among patients with stented BPs, porcine valves were associated with a lower risk of HVD than pericardial BPs (Table 1 and Figure 2 ).
After adjusting for age, sex, hypertension, creatinine clearance, use of warfarin, and statin (Table 1) , type of BP, diabetes mellitus, baseline postoperative MG ≥15 mm Hg, and severe PPM were independently associated with overall HVD. In a model built containing additional multivariable models, the key variables associated with HVD remained unchanged (Table VII in In multivariable analysis, diabetes mellitus, active smoker, creatinine clearance <30 mL/min (versus >60mL/min), stented BP (versus stentless BP), baseline postoperative MG ≥15 mm Hg, and transprosthetic regurgitation greater than or equal to mild were independently associated with HVD occurring during the first 5 years after surgery (ie, very early and early SVD pooled together) ( Table 2 ). Warfarin use, female sex, and stented BP were independently associated with HVD detected beyond the fifth year after surgery (ie, midterm and long-term HVD pooled together) ( Table 2) .
Association Between HVD and Outcomes
During follow-up (median time 10.5 [7.6-13.8] years), 159 (11.5%) patients underwent a reintervention because of BP valve failure, and 724 (52.2%) died. Twentysix (1.9%) patients underwent redo aortic surgery for a reason other than BP valve failure (eg, pannus, paravalvular regurgitation, thrombus, infective endocarditis).
All patients who underwent a reintervention because of BP valve failure had evidence of HVD detected during the echocardiographic follow-up. However, among the 428 patients with HVD, only 159 (37.1%) underwent a reintervention for aortic BP valve failure (redo surgery: n=126; transcatheter valve-in-valve: n=33) at a median time of 4.2 (0.5-26.8) months after the detection of HVD (Table VI in the online-only Data Supplement). Mechanisms of HVD involved in the patients who underwent reintervention for BP valve failure are shown in the Results in the online-only Data Supplement. All 126 patients who underwent surgical replacement of the failed BP had evidence of structural valve deterioration (ie, fibrocalcific remodeling of valve leaflets) at examination of the explanted valve by the pathologist. None of the patients had evidence of BP valve thrombosis or endocarditis.
HVD expressed as a time-dependent variable was independently associated with death from any cause (hazard ratio [HR], 2.18; 95% CI, 1.86-2.57; P<0.001) ( Table 3 and Figure 3 ). However, reintervention for aortic BP failure was not associated with mortality (P=0.29).
Reintervention for aortic BP valve failure was more frequent in patients with midterm or long-term HVD (Table  VI in (Figure 4 ). Long-term HVD was not significantly associated with mortality (HR, 1.35; 95% CI, 0.82-2.19; P=0.23). In a multivariable Cox proportional hazard analysis with baseline (time zero) at the time of surgery, probabilities of survival were lower in patients with HVD occurring earlier during postoperative follow-up (Figure 3) . However, when this analysis 
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was repeated with the baseline set at the time of HVD detection, the survival probabilities were not significantly different in all 4 groups of HVD timing (Figure 3 ).
DISCUSSION
The main findings of this study are: (1) HVD, documented by serial Doppler echocardiography, occurred in ≈30% of surgical BP aortic valve recipients; (2) HVD was independently associated with mortality; and (3) the main factors associated with early SVD were diabetes mellitus, renal failure, and PPM, whereas those associated with late HVD were female sex, warfarin use, stented (versus stentless) BP, and pericardial (versus porcine) BP.
Definition, Rate, and Associations With Outcomes of HVD
In most previous studies, the incidence of SVD after bioprosthetic AVR was based on the need for valve reintervention because of structural valve failure, including leaflet calcification and tear as well as stent creep and detachment of leaflet from the stent suture line disruption. 1, 7, 9, 10 However, guidelines for reporting morbidity and mortality after cardiac valve interventions also include in the definition of SVD the presence of hemodynamic valve dysfunction determined by clinical and echocardiographic investigation. 3 In the study of Bourguignon et al, 14 which included 2659 patients, 123 (6%) had severe BP valve dysfunction after AVR, which was defined as a mean gradient ≥40 mm Hg or severe transprosthetic regurgitation. Of these 123 patients with severe valve hemodynamic dysfunction, 78% underwent reoperation and 14% died soon after the echocardiographic diagnosis. Senage et al 15 reported a higher rate of early SVD compared with our series. However, this prior study used a different definition for HVD, and more important, it included a series of patients who all underwent AVR with the same type of BP (ie, the Mitroflow BP, known to be associated with an increased risk of early valve failure). 16 In this latter study, BP dysfunction was the strongest predictor of mortality in multivariable analysis (HR, 7.7). 
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In the present study, the rate of valve reintervention was much lower (11.5%) compared with the rate of HVD documented by Doppler echocardiography (30.9%). Hence, a definition of SVD based on the assessment of valve hemodynamic function by Doppler echocardiography during follow-up is essential to determine the true incidence of SVD. [4] [5] [6] However, valve reintervention is generally performed in patients having severe BP hemodynamic dysfunction, whereas the definition of HVD that we used in this study includes both moderate and severe grades of BP hemodynamic dysfunction. Nevertheless, the occurrence of HVD during follow-up was associated with worse clinical outcomes. Indeed, HVD was independently associated with a 2.2-fold higher risk of mortality. The high incidence of HVD and its association with higher mortality may contribute to explain the results of previous studies that reported better survival with mechanical AVR compared with biological AVR, despite similar rates of reoperation in the midterm postoperative period. [17] [18] [19] However, a recent study reported that among patients who underwent AVR when >55 years of age, the implantation of a biological valve was associated with higher rates of valve reintervention but similar survival compared with implantation of a mechanical valve. 20 Furthermore, the association between SVD and outcomes was more pronounced when it was detected earlier in the postoperative period, with HVD occurring beyond 10 years after AVR showing no association with increased mortality. However, the probability of death calculated with time zero corresponding to the first detection of HVD (instead of time of AVR) was similar regardless of the timing of HVD after AVR. The definition of HVD used in the present study is based on the Doppler echocardiographic parameters and criteria proposed by the European Association of Cardiovascular Imaging for the imaging assessment of prosthetic valves, 4 which has been used in some recent studies. 21, 22 Two recent consensus statements on the standardized definitions of SVD have highlighted the importance of the assessment of valve hemodynamic function during follow-up to identify and quantify SVD 
after AVR. 5, 6 The definition of HVD used in the present study is actually in line with the stage 2 SVD proposed by the VIVID experts group 6 and with the moderate hemodynamic SVD proposed by the European Association of Percutaneous Cardiovascular Interventions and endorsed by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. 5 The strong association between SVD-related HVD and mortality reported in the present study provides a strong, a posteriori, validation of these standardized definitions of SVD recently proposed by medical societies and groups of experts. 
HVD may occur as a result of SVD but also as a result of valve thrombosis or endocarditis. This finding raises the importance of comprehensive assessment of valve leaflet morphology by using transthoracic or transesophageal echocardiography to identify the underlying etiology of HVD. 4 In the present study, we included only patients with HVD related to SVD. However, we cannot exclude the possibility that non-SVD etiologies, and particularly subclinical valve thrombosis, may have contributed to HVD in some cases of our series. Del Trigo et al 22 reported an incidence of very early SVD (first 2 years after procedure) after transcatheter AVR to be 4.5%. In the present study using the same HVD definition as Del Trigo et al, 22 we found an incidence of 3.7% of very early HVD after surgical AVR. In our series, very early HVD was associated with a 2.5-fold higher all-cause mortality, whereas in the study of Del Trigo et al, 22 very early HVD had no such association. However, the follow-up was short (2 years after procedure) in this latter study. Hence, these findings do not necessarily support the concept that early SVD is less frequent after surgical versus transcatheter AVR. For HVD within the late phase (midterm and long-term), there is no reported transcatheter AVR echocardiographic follow-up to date.
The American Heart Association/American College of Cardiology Guidelines for managing patients with valvular heart disease recommend yearly TTE follow-up but only 10 years after AVR, 23 whereas the American Society of Echocardiography Guidelines recommend yearly follow-up beyond 5 years.
11
In the present study, ≈80% of the HVD cases were detected before 10 years after AVR and 42% before 5 years after AVR. These findings thus provide support to the recent recommendations of the European Society of Cardiology/European Association for Cardio-Thoracic Surgery recommendation of a closer and more systematic follow-up after AVR with the performance of TTE at discharge, at 30 days, and annually thereafter to allow earlier detection of HVD. 24 When HVD is detected, a strategy of reevaluation 3 to 6 months later in case of moderate hemodynamic dysfunction and valve reintervention according to treatment guidelines in case of severe valve hemodynamic dysfunction should be considered. 5, 6 In the present study, the rate of transcatheter valve-in-valve intervention in patients with severe HVD was low compared to that of surgical redo AVR (20.8% versus 79.2%, respectively). However, the rapid expansion of the valve-in-valve procedure could allow the reduction of the impact of HVD on outcomes.
Factors Associated With HVD
Renal failure has been previously associated with accelerated SVD of BP valves, 25 and this association was also found in the present study. Diabetes mellitus was strongly associated with HVD, especially early SVD in the present study. We also previously reported that metabolic syndrome is associated with faster deterioration of BP hemodynamic valve function. 26 In a large Italian multicenter registry, Lorusso et al 27 reported that diabetes mellitus is associated with a 2.4-fold increase in the risk of reoperation for structural valve failure. There is thus a growing body of evidence purporting diabetes mellitus as a strong risk factor for SVD after BP AVR. Diabetes mellitus is associated with abnormal low-density lipoprotein particle phenotype (small dense low-density lipoprotein particles) and with chronic inflammatory and oxidative states, which may promote lipid-mediated inflammation and degeneration of prosthetic valve leaflets. 28, 29 Other factors typically associated with diabetes mellitus may also accelerate SVD, including (1) accumulation of advanced glycation end products that trigger oxidative stress, 30 and (2) reduced carboxylation and activity of Matrix-gla protein (ie, a protective factor against ectopic calcification). 31 Diabetes mellitus is also a strong risk factor for valve thrombosis and endocarditis after BP AVR. 32, 33 These pathological processes, even if treated successfully, may in turn lead to BP SVD and 
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HVD. As opposed to a previous study by AntoniniCanterin, 34 we did not find any association between statin use and a lower risk of HVD.
The positive association between active smoking status and early SVD provides further corroboration for the results of prior studies linking smoking and SVD. 35, 36 Although it remains to be determined, it is possible that increased oxidative stress in smokers may impact on SVD. 30 Emerging evidence indicates a link between altered bone mineralization metabolism, particularly osteoporosis, and ectopic calcification. [37] [38] [39] It remains unclear whether this calcification paradox also applies to BPs. 40, 41 Nonetheless, in the present study as well as in the previous study by Senage et al, 15 female sex was associated with a higher risk of HVD. The vast majority of women included in this study were postmenopausal, and thus they were predisposed to ORIGINAL RESEARCH ARTICLE osteoporosis. It is interesting to note that vitamin K deficiency is a common factor in the development of both osteoporosis and arterial calcification. 42 The vitamin K antagonist warfarin has also been associated with increased risk of arterial calcification and native aortic valve calcification. 43, 44 To our knowledge, the present study is the first to report independent association between prolonged warfarin therapy and Kaplan-Meier curves and log-rank test of the time-to-event data were used to compare the association between very early, early, midterm, and long-term HVD and death from any cause. For very early, early, and midterm HVD, the baseline (time zero) of the follow-up period was set at the date of the first echocardiographic diagnosis of HVD for patients with HVD and the end of the studied time subperiods for patients without HVD (ie, 2, 5, and 10 years, respectively). For long-term HVD, the baseline time was set at 10 years after aortic valve replacement for all patients. Hazard ratio (HR), 95% CI, and P value were obtained by a multivariable Cox analysis after adjustment with the other variables. A, Association with very early HVD in the whole cohort of patients (n=1387). B, Association with early HVD in the cohort of patients (n=926) with a sufficient follow-up and no very early HVD. C, Association with midterm HVD in the cohort of patients (n=385) with sufficient echocardiographic follow-up and no very early or early HVD. (Continued ) SVD-related HVD. Warfarin prevents the activation of some vitamin K-dependent proteins such as Matrix Gla Protein and Growth Arrest Specific Gene 6, which prevent arterial calcification. Further studies are needed in patients requiring anticoagulation to determine whether nonvitamin K antagonist oral anticoagulants are associated with longer BP durability after AVR compared with warfarin.
PPM, residual transprosthetic gradient, and regurgitation after AVR were associated with increased risk of HVD during follow-up. These factors may increase the mechanical stress on the BP valve leaflets and cause abnormal flow patterns at the surface of the leaflets, which may in turn accelerate SVD. 45 The results of this study as well as those of previous studies 46, 47 further emphasize the importance of efforts made to prevent PPM at the time of surgical AVR to optimize the BP durability. Stentless BPs were associated with less HVD than stented BPs. This difference may be related to the fact that stentless BPs, by virtue of their design, may have less mechanical stress on the valve leaflets, less turbulent transvalvular and postvalvular flow, and thus less PPM. 48 Several previous studies reported that younger age at the time of AVR is associated with an increased risk of SVD. 9, 10, 27, 36 However, in these studies, SVD was defined on the basis of reoperation for structural valve failure, and therefore younger patients with SVD have a much higher likelihood to be reoperated than their elderly counterparts with the same degree of SVD. Elderly patients often harbor substantial comorbidities and may be declined for surgical reoperation or even a transcatheter valvein-valve procedure. In the present study, age at AVR was not associated with an increased risk of SVDrelated HVD assessed by Doppler echocardiography. The absence of association between age and HVD should be interpreted with caution and may be related, at least in part, to the relatively old age in the present cohort.
Limitations
This is a retrospective analysis of prospectively collected data from a single, large-volume surgical center. The TTE follow-up protocol used in the present study was not as well standardized as in a prospective trial, but it has the advantage of representing the real-life practice. The major limitation of this study is that only patients who survived the perioperative period and had complete echocardiographic follow-up in our center were included. On the one hand, a potential concern is thus that these survivorship and follow-up biases may have contributed to overestimate the rates of HVD in the present study. On the other hand, patients excluded from the study because of absent or incomplete echocardiographic follow-up actually exhibited a higher prevalence of risk factors for HVD and SVD (ie, diabetes mellitus, active smoking status, warfarin use, stented BP, and BP with size ≤21 mm) (Tables I and II in the online-only Data Supplement) as well as higher rates of late mortality ( Figure II in the online-only Data Supplement) compared with patients included in the study. Hence, these findings suggest that the incidence of HVD and SVD was most likely at least as high, if not higher, in the excluded cohort than in the included cohort. The retrospective design of this study does not allow us to provide a definite conclusion regarding the actual incidence of HVD after SAVR, and future prospective studies are needed to confirm this finding.
Clinical data on postoperative patient functional status and rehospitalizations as well as data on serum cholesterol levels and the statin treatment status during the follow-up were not available. Data on stroke volume, heart rate, and hemoglobin at the time of echocardiography were not collected. These factors may have influenced the changes in ORIGINAL RESEARCH ARTICLE MG during follow-up. In particular, an increase in MG during follow-up could be related to an increase in left ventricular ejection fraction and stroke volume in the absence of any SVD. However, in such a case, the increase in MG is associated with a concomitant increase or no change in prosthetic valve effective orifice area and no morphological changes in valve leaflets. In the present study, we used a definition of HVD that is based on an increase in MG ≥10 mm Hg associated with a concomitant decrease in valve effective orifice area and with morphological abnormalities of valve leaflets. This definition, which has been recommended by medical societies and expert groups [4] [5] [6] to define HVD related to SVD, thus excludes a potential increase in transprosthetic gradient related to an increase in flow. Furthermore, in the subset of patients with HVD occurring within the first 5 years after AVR, the left ventricular ejection fraction did not change significantly from baseline after AVR and follow-up echocardiograms.
CONCLUSIONS
In this large series of patients who underwent AVR with a BP, HVD as documented by Doppler echocardiography occurred in 30% of patients and was associated with 2.2-fold higher mortality. Diabetes mellitus and renal insufficiency were associated with a higher risk of early (<5 years) HVD, whereas female sex, warfarin use, stented (versus stentless) BP, and pericardial (versus porcine) BP were associated with a higher risk of late (>5 years) HVD. These data also provide strong, a posteriori, validation of the standardized definitions recently proposed by medical societies and group of experts for SVD of aortic bioprostheses based on valve morphological and hemodynamic changes assessed by Doppler echocardiography during follow-up. Further multicenter prospective studies are needed to confirm these findings in contemporary surgical and transcatheter AVR series. 
ARTICLE INFORMATION
